IQVIA OneKey Alternatives: HCP Data Options Compared (2026)

What OneKey actually is, by IQVIA's published numbers

OneKey is IQVIA's global reference database of healthcare professionals and organisations, delivered by API and pre-built connectors into CRM, master data management, analytics and ERP systems. IQVIA publishes coverage of approximately 25 million HCPs and 6 million HCOs across 118 countries, used by more than 2,000 organisations, with 250 to 1,000 attributes per professional, roughly 17.5 million proactive real-time updates each month, over 99% of updates automated, and around 1,000 research associates specialising in local healthcare systems. It carries ISO 27001, SOC 2 Type II and HIPAA certifications and reports an opt-out rate below 0.08%.
Set that out plainly before comparing anything, because it establishes what a substitute would have to replicate. Country breadth at that scale is the product of decades of local research operations. The attribute range is what makes segmentation, affiliation mapping and compliance flagging possible in one file. And the update volume is the part that is genuinely hard to buy elsewhere: a file is only as good as the process that keeps it current, and 17.5 million monthly proactive updates is an industrial operation, not a data extract.

There is one caveat worth noting for anyone quoting these numbers. IQVIA publishes slightly different figures across different assets — 118 countries on the OneKey product page against 110 on the Data Partner Program fact sheet, and approximately 1,000 research associates on the product page against a figure closer to 300 data operators on the 2025 United States reference data fact sheet. These are not contradictions so much as different scopes and vintages, but cite the specific asset and date rather than treating any one number as canonical.

IQVIA OneKey vs alternatives

Only Veeva OpenData is a genuine global substitute for OneKey, and the two are close enough that the decision usually turns on your surrounding stack rather than on the data. Below that, the category splits into United States-only files with flexible commercial terms, regional specialists with depth in one market, marketplaces that broker other people's datasets, and the free public NPI registry. Choose a substitute only if you need global breadth from a different vendor; otherwise you are choosing either a complement or a smaller-scope product for an earlier commercial stage.

On the OneKey versus OpenData question specifically, the honest position is that both are excellent and the published counts are not directly comparable, because the two providers curate to different inclusion criteria and report coverage differently — OneKey as a single global figure, Veeva regionally. What used to differentiate them was the risk of depending on either company's data inside the other's technology. That ended on 18 August 2025, when both sides dismissed eight years of litigation with prejudice and signed multi-year data integration agreements. We covered what that means for buyers in Veeva OpenData alternatives.

The real question is sizing, not quality

Companies rarely leave OneKey because the data is inadequate. They leave, or never buy, because the product is scaled for a commercial operation they do not yet have — global breadth, a thousand attributes per record and an industrial update process, priced and contracted accordingly. Match the data product to your commercial stage: a first launch needs a few hundred accurate accounts, a single-region mid-cap needs one or two markets in depth, and only a genuine multinational needs a global reference spine.

The pattern worth internalising is that this is a staging decision with a natural progression, and the expensive mistakes happen when a company buys a stage ahead of where it is. It is far easier to expand a scoped licence than to justify an enterprise contract to a board eighteen months before the commercial operation exists to use it.

HCP data vendor comparison for emerging pharma

This question has two distinct audiences and they need opposite answers. In standard industry usage, “emerging pharma” means emerging biopharma — companies with under $500 million in annual sales and under $200 million in R&D spend, usually approaching a first launch. For them the answer is a deliberately narrow, high-quality universe. But many readers mean pharma operating in emerging markets, where the constraint is the opposite: global files are curated thin and local depth is the requirement. Establish which one you are before reading any comparison, including this one.
The ambiguity is not pedantry. It routinely produces the wrong purchase, because a vendor hearing “emerging pharma” will assume the first meaning and pitch a scaled-down United States product to a company whose actual problem is prescriber coverage in Uttar Pradesh. Both readings are addressed below, in that order.

Reading one: emerging biopharma companies

This segment now dominates innovation. IQVIA Institute research found emerging biopharma accounted for roughly 67% of the R&D pipeline in 2022, up from about 33% two decades earlier, with 65% of pipeline molecules having no larger company involved, and EBP-originated products representing 55% of novel active substances launched over the preceding decade. The number of such companies rose 26% over five years.

The same research contains a warning that should shape every commercial infrastructure decision these companies make. For launches between 2016 and 2020, median sales at year two were seven times higher when a larger company commercialised the product than when the originating emerging biopharma self-commercialised. Commercial execution, not science, is where the value gap opens. Data is one of the earliest and most reversible of those execution decisions, which makes getting its size right unusually consequential.

The competing content on this keyword is worth understanding. The most visible ranker, updated 30 March 2026, compares platform categories rather than named products, positions its own publisher as the mid-market recommendation, quotes no pricing for any vendor, and contains no discussion of India, emerging markets or any non-United States geography. It is a reasonable page for a United States mid-market buyer and no help at all to anyone else.

Reading two: pharma operating in emerging markets

If this is your reading, the constraint inverts. You are not trying to buy less of a global file; you are trying to reach prescribers the global file was never scaled to include. The arithmetic is stark in India: Veeva OpenData publishes coverage of approximately one million HCPs across all eleven of its Asia Pacific countries combined, while India alone had 13,86,136 registered allopathic doctors as of July 2024. OneKey's global figure of 25 million across 118 countries implies a similar structural reality — these are curated commercial universes, which is exactly what a global reference file should be, and exactly why they thin out in the long tail of any single emerging market.

The architecture that follows is the same one we recommended in the OpenData guide, and it is the one Veeva itself uses in Japan, where it partners with a local specialist rather than maintaining its own file. Keep the global spine for identity and cross-market consistency. Add local depth only where the arithmetic says the global file cannot reach. Our own view of the Indian provider landscape is set out in best doctor and HCP data providers in India.

What the free option can and cannot do

NPPES, the CMS National Plan and Provider Enumeration System, publishes every National Provider Identifier holder in the United States as a free bulk file updated weekly and monthly. It is a legitimate starting baseline for a pre-launch or first-launch United States universe and a poor finishing point: taxonomy is self-reported, there is no reliable deactivation for retirement or death, addresses are frequently stale, and it carries no affiliations, hierarchy, channel preference or consent state. It is also United States only, which makes it irrelevant to most of this article's second audience.
The reason to take it seriously anyway is sequencing. A pre-commercial company can build a credible first target universe from the public registry plus manual curation, discover what its actual universe looks like, and then buy a scoped licence against a known requirement rather than a guessed one. Companies that skip this step routinely license national coverage to support a list of four hundred accounts.

Unbundling reference data from a wider IQVIA relationship

Many companies searching for OneKey alternatives are not unhappy with OneKey. They are trying to establish what reference data costs on its own, inside a master agreement that also covers prescription data, claims, analytics or consulting. That is a commercial architecture question rather than a vendor question, and it is usually better resolved in renewal negotiation than by switching. Ask for the reference data line to be priced and termed separately before you evaluate anyone else.
This matters because bundling changes the arithmetic in both directions. Reference data inside a large relationship may be priced more favourably than it would be standalone, in which case moving it out costs more than it saves. Or it may be carrying countries and attribute depth added for a footprint that has since changed, in which case the saving is available without any vendor change at all. You cannot know which without an itemised view, and vendors do not volunteer one.

One sequencing constraint applies to almost everyone in this market. Veeva moved legacy CRM end of support to the end of December 2029, which already compresses migration planning for anyone still on it. If a reference data decision and a CRM migration are both in front of you, separate them deliberately — and if you cannot, that is itself an argument for renegotiating scope rather than changing vendors.

A staged data strategy from pre-launch to multi-market

The steps below are a sequence rather than a schedule, because the right pace depends on your launch timeline. What matters is the order: each step produces the information the next one needs, and skipping ahead is what produces oversized contracts.

1. Establish which “emerging” you are. Write down whether your constraint is company scale — under $500 million in sales, approaching first launch — or geography, meaning prescribers in markets where global files are curated thin. Every subsequent decision differs between the two, and vendors will assume the first unless told otherwise.
2. Build the target universe before buying coverage. For a United States launch, start from the public NPI registry and your medical affairs relationships. For an emerging market, start from your own field records. In both cases the output is a count: how many prescribers actually matter. Most first-launch teams are surprised by how small it is.
3. Verify the small list properly. Primary verification is affordable at hundreds of records and prohibitive at hundreds of thousands. Spend here while the universe is small — accuracy on a target list is worth more at launch than breadth ever will be.
4. Buy affiliations and hierarchy before you buy volume. Organisational structure is the attribute class that reference data does best and that you cannot reconstruct cheaply. It drives account planning, contracting and compliance reporting. Volume can wait; hierarchy cannot.
5. Scope the licence to therapy area and geography. Ask explicitly for a scoped commercial construct rather than accepting national or global as the default unit. Agree expansion pricing at signature, so that growth is a decision rather than a renegotiation.
6. Stand up consent capture in parallel, not afterwards. A reference licence gives you identity and reachability. It does not give you permission to promote. Build the consent record against the prescriber from the first campaign, and enforce it at send rather than in reporting.
7. Add local depth only where the arithmetic demands it. When you enter a market where the global file is a curated subset, layer a local provider against that market and test it at district level against practitioners your own team knows. Do not replace the spine.
8. Re-examine scope at every renewal. Footprints drift faster than contracts. Reconcile licensed countries and attribute tiers against actual commercial operations annually, and negotiate re-entry terms whenever you narrow.

Treat the first two steps as gating. A company that has not written down which “emerging” it is, and has not counted its actual target universe, is not ready to compare vendors — and will be sold whatever the first vendor in the room happens to sell.

Where Multiplier AI fits — and where it does not

We are a local depth layer for emerging markets. Against OneKey specifically, our boundaries are wide and worth stating without hedging.

Do not shortlist us if

• You need a global reference file. We do not maintain HCP and HCO reference data across 118 countries, we do not process seventeen million updates a month, and we are not building towards either. That is OneKey and Veeva OpenData, and there is no third option at that scale.
• Your launch is in the United States or Western Europe. Our depth is in India and other emerging markets. For a first United States launch, the sensible path is the public registry, a scoped enterprise licence and targeted verification — none of which involves us.
• You need affiliation hierarchy at enterprise scale. Organisational structure across health systems and networks is where enterprise reference data genuinely earns its price. Do not economise on it, and do not expect a local specialist to replace it.
• Your problem is master data management. If duplication and survivorship inside your own systems is the issue, buying more data will make it worse. Fix the MDM layer first.

Do shortlist us if

• Your growth is in markets where the global file is necessarily curated. Tier-2 and tier-3 India is the specific case, and it is where the coverage arithmetic bites hardest.
• You need behavioural depth rather than identity. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters, which is a different job from maintaining a compliant global identity record.
• Your existing doctor master needs cleaning before any purchase. The discrepancy rate we observe in pharma CRM doctor records is around 57%, and resolving it usually changes what you need to buy.
• You want verification connected to execution. Corrected records flow into our Hyper Personalized Content Platform, so a fixed record changes what actually gets sent rather than sitting in a system.

The mistakes that make this decision expensive

• Understating OneKey in order to justify an alternative. If your comparison does not acknowledge 118 countries, 250 to 1,000 attributes and seventeen million monthly updates, it is not a comparison and your board will notice.
• Buying a stage ahead of your commercial operation. Enterprise global contracts signed eighteen months before the field force exists are the most common overspend in this category.
• Not establishing which “emerging” you are. The two readings lead to opposite architectures, and vendors default to the one they sell.
• Economising on affiliations and hierarchy. It is the attribute class that is hardest to rebuild and most consequential for account planning. Volume is negotiable; structure is not.
• Switching when the real issue is bundling. Ask for the reference data line to be priced and termed separately before evaluating anyone else. The saving is often available without a vendor change.
• Treating a licence as marketing permission. Reference data gives you identity and reachability. Consent for promotional contact is a separate programme with its own budget, and under DPDP it must be enforced at send.
• Running the change through a CRM migration. With legacy Veeva CRM support ending December 2029, these windows will collide unless separated deliberately.

Buy the stage you are in

The reason this keyword produces so much low-quality content is that “alternative” implies inadequacy, and OneKey is not inadequate. On published figures it is the most comprehensively maintained healthcare professional reference file in the world, and the honest competitive statement is that only one other product operates at that scale. Any page that begins by suggesting otherwise has told you what it is selling before it has told you anything useful.

What is true is that the product is built for a commercial operation many buyers do not yet run. An emerging biopharma approaching its first launch needs a few hundred prescribers profiled accurately and an affiliation structure it can plan accounts against — not a hundred and eighteen countries. A company growing in India needs depth in districts that no global file was scaled to prioritise. Neither of those is a criticism of OneKey. They are descriptions of different problems, and buying the wrong size is expensive in both directions: too much, and you fund coverage you never use; too little, and you rebuild the identity layer under a live commercial operation.

IQVIA's own research found that emerging biopharma companies self-commercialising a launch achieved median year-two sales seven times lower than when a larger company ran it. Commercial infrastructure decisions are where that gap is made. Get the size right, and get it right early.

Frequently Asked Questions For IQVIA OneKey Alternatives